Comple­tion of recruit­ment of patients in the study of the drug for the treatment of COVID-19

The recruitment of patients to phase III studies of a Russian drug for the treatment of patients with COVID-19 has been completed ahead of schedule.

This drug is intended for the treatment of a wide range of viral infections and is a purine nucleoside that acts as a competitive inhibitor of viral RNA-dependent RNA polymerase. The study involved more than 20 clinical centers and 158 people.